Multidrug resistance (MDR) is a major obstacle in effective
chemotherapy for
cancer patients. The expression of
P-glycoprotein (P-gp) in
cancer cells is highly correlated with resistance to chemotherapeutic drugs. (-)-
Antofine, a
phenanthroindolizidine alkaloid derived from Cynanchum paniculatum, inhibits the growth of various human
cancer cells. In this study, we further explored the potential of (-)-
antofine to overcome the resistance induced by anti-
cancer drugs. To this end, we established the
paclitaxel-resistant human
lung cancer cell line A549-PA by gradually exposing A549 cells to increasing concentrations of
paclitaxel. As a result, the A549-PA cells acquired resistance against
paclitaxel treatment and had an IC50 that was more than 200 times that of the parental A549 cells. (-)-
Antofine, however, effectively suppressed the growth of both the parental and
drug-resistant cells. Additional studies revealed that the anti-proliferative activity of (-)-
antofine in A549-PA cells is accompanied by a down-regulation of P-gp
mRNA and
protein expression. The effect of reversing the multidrug resistance of A549-PA cells via (-)-
antofine treatment was demonstrated an increase in intracellular rhodamine-123 accumulation, measured using FACS analysis. These findings suggest an additional chemotherapeutic value of (-)-
antofine, that is, regulation of
cancer cell drug resistance, in addition to its antitumor effect.